Compare Summit Therapeutics Inc (SMMT) vs Uber Technologies Inc (UBER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Uber Technologies Inc — how do they compare? Summit Therapeutics Inc trades at $17.38 (market cap $13.71B), while Uber Technologies Inc trades at $70.2 (market cap $143.47B). The key difference: Uber Technologies Inc is far larger — about 10.5× Summit Therapeutics Inc's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Uber Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Uber Technologies Inc for 88 Days on average.
| SMMT | UBER | |
|---|---|---|
Market Cap | $13.71B | $143.47B |
Volume | 6,173,057 | 14,430,657 |
Sector | Health | Technology |
52-Week High | $26.38 | $99.72 |
52-Week Low | $12.43 | $65.94 |
Typical Hold Time | 16 Days | 88 Days |
Enterprise Value | $13.04B | $152.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.95, up 3.7% with strong technical momentum and bullish analyst sentiment. The stock shows negative profitability metrics but benefits from AstraZeneca's $2 billion strategic investment and clinical collaborations. Recent news highlights positive clinical trial results for ivonescimab, driving investor optimism despite current financial losses.
The outlook remains speculative with significant upside potential based on analyst consensus targets averaging $29.33, though high valuation multiples and negative cash flows present substantial risk. Success of clinical trials and partnership execution will determine long-term value creation for shareholders.
Uber trades at $68.45, down 0.91% on the day, with a bearish technical signal despite strong fundamentals. The company reported $52.02B revenue in 2025 with $10.05B net income, maintaining robust growth from $44.0B revenue in 2024. Recent expansion includes the Costco delivery partnership reaching 47 states, while CEO Dara Khosrowshahi purchased $10 million in shares, signaling confidence.
Uber presents a compelling growth story with expanding profitability and dominant market position, though technical indicators suggest near-term pressure. The consensus price target of $104.72 implies 53% upside, supported by 82.5% analyst buy ratings. Key risks include robotaxi competition and projected negative cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
